Redwoods Acquisition Corp. (RWOD) Signs Agreement of Intent with Xin Bo Xing
by Nicholas Alan Clayton on 2022-12-16 at 2:53pm

Redwoods Acquisition Corp. (NASDAQ:RWOD) announced in a 425 filing that it has signed an agreement of intent to combine with material technology company Xin Bo Xing.

The parties intend to arrange a PIPE for the transaction involving several private funds and the combined company would be listed on the Nasdaq, according to the filing.

Xin Bo Xing (also spelled Xinboxing elsewhere in the document) is focused on developing precision casting technology using titanium and zirconium alloys. It also produces products for clients under an original design manufacturing (ODM) model, which is common in the Chinese manufacturing space.

Under this model, the supplier, in this case Xin Bo Xing, owns the design for the product and the customer can either take this design as is or tweak it slightly while putting their own logo and aesthetics on it.

Western and multinational manufacturers more commonly use the original equipment manufacturer (OEM) model, where they build parts to client’s specifications. But, such an approach requires greater resources and flexibility in both the company’s R&D and machining capabilities.

The filing includes little additional detail on Xin Bo Xing other than it possesses about 100 national patents. The company also does not appear to have a web presence – at least not in English.

Redwoods is led by CEO Jiande Chen who serves on the board IMAX China (HKG:1970), which is the national licensee of the IMAX cinematic technology, and the Beijing Cultural Investment Development Group (SH:600715).

The SPAC’s CFO Edward Cong Wang also serves as CEO of Pacifico Acquisition Corp. (NASDAQ:PAFO) and the two SPACs share a director in common.

Pacifico is currently in an unusual situation, working to close its combination with shipping technology company Caravelle after all but 25,079 of its shares were redeemed at its November 30 completion vote. It has since made a contribution to its trust to extend its deadline, giving it technically a $33.32 per share in trust value, but shareholders will be unable to redeem further.

Redwoods will be hoping to avoid such a limbo situation and has until April 4, 2023 under its initial deadline with the ability to extend by three months twice via a contribution to the trust.

 

Recent Posts
by Nicholas Alan Clayton on 2024-07-24 at 4:38pm

Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...

by Nicholas Alan Clayton on 2024-07-24 at 1:19pm

FTAC Emerald (NASDAQ:EMLD) has entered into a definitive agreement to combine with crypto fintech firm Fold at an enterprise value of $381 million. Phoenix, Arizona-based Fold provides digital banking services backed by a treasury of Bitcoin that includes FDIC-secured checking accounts as well Bitcoin trading and awards. The combined company is expected to trade on...

by Nicholas Alan Clayton on 2024-07-24 at 8:19am

At the SPAC of Dawn Dealmakers remain confident that AI is going to play a big role in their M&A processes, but feel unprepared for some the changes, according to a new survey of 225 corporate and 75 private equity transactions professionals. SS&C subsidiary Mergermarket generated the report that found more than half of respondents...

by Nicholas Alan Clayton on 2024-07-23 at 4:33pm

Trailblazer Merger I (NASDAQ:TBMC) has entered into a definitive agreement to combine with data intelligence firm Cyabra at an enterprise value of $70 million. Tel Aviv-based Cyabra provides tools to corporations and governments to identify fake accounts and combat social media disinformation. The combined company is expected to trade on the Nasdaq once the deal...

by Nicholas Alan Clayton on 2024-07-23 at 1:00pm

Chain Bridge I (NASDAQ:CBRG) has entered into a definitive agreement to combine with cannabinoid pharmaceuticals firm Phytanix Bio at a pre-deal valuation of $58 million. Santa Barbara, California-based Phytanix is working to develop bladder and seizure treatments using cannabis-based substances. The combined company is expected to trade on the Nasdaq under the symbol “PHYX” once...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved